AC	Doxorubicin and Cyclophosphamide
AD	Axillary Dissection
CI	Confidence Interval
DCIS	Ductal Carcinoma in Situ
DRFS	Distant Recurrence-Free Survival
EFS	Event-Free Survival
ER	Estrogen Receptors
HER2	Human Epidermal Growth Factor Receptor 2
ICIs	Immune Checkpoint Inhibitors
IDC	Invasive Ductal Carcinoma
ILC	Invasive Lobular Carcinoma
IMC	Invasive Mammary Carcinoma
iRAEs	Immune-Related Adverse Events
KHCC	King Hussein Cancer Center
LN	Lymph Node
LRFS	Locoregional Recurrence-Free Survival
NACi	Neoadjuvant Chemotherapy with Immunotherapy
NACT	Neoadjuvant Chemotherapy
OR	Odds Ratio
OS	Overall Survival
pCR	Pathological Complete Response
PD-L1	Programmed Death-Ligand 1
PR	Progesterone Receptors
PSM	Propensity Score Matching
RFS	Recurrence-Free Survival
SD	Standard Deviation
SMDs	Standardized Mean Differences
SSI	Surgical Site Infection
TMB	Tumor Mutational Burden
TNBC	Triple-Negative Breast Cancer